Evidence map›Paper›PMID 33966093›Full record

ReviewCancer immunology, immunotherapy : CII2021

Brief in vitro IL-12 conditioning of CD8

Mohamed Labib Salem, Samar Salman, Ibrahim O Barnawi

Open access · greenAbstract readReview
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Ferroptosis: CD8Cell death discovery · 2025
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Mohamed Labib SalemImmunology and Biotechnology Unit, Zoology Department, Faculty of Science, Tanta University, Tanta, Egypt. mohamed.labib@science.tanta.edu.eg.ORCID http://orcid.org/0000-0003-0840-5291
Samar SalmanDepartment of Dermatology and VenereologyFaculty of MedicineTanta University Hospital, Tanta University, Tanta, Egypt.
Ibrahim O BarnawiAnimal Section, Department of Biological Sciences, Faculty of Science, Taibah University, Medina, Saudi Arabia.
Taibah University · SATanta University · EGTanta University Hospital · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy represents a potential treatment approach through non-specific and specific enhancement of the immune responses. Adoptive cell therapy (ACT) is a potential modality of immunotherapy that depends on harvesting T cells from the tumor-bearing host, activating them in vitro and infusing them back to the same host. Several cytokines, in particular IL-2, IL-7 and IL-15, have been used to enhance survival T cells in vitro. Although effective, conditioning of T cells in vitro with these cytokines requires long-term culture which results in the loss of expression of their trafficking receptors mainly CD62L. It also results in exhaustion of the activated T cells and reduction in their functions upon adoptive transfer in vivo. Our recent studies and those of other groups showed that brief (3 days) conditioning of CD8

Indexed as

AnimalsCD8-Positive T-LymphocytesCell- and Tissue-Based TherapyHumansImmunotherapyInterleukin-12MiceInterleukin-12Adoptive cell therapyCancerCyclophosphamideCytokineIL-12Immunotherapy

Identifiers

PMID33966093
PMCPMC10992799
OpenAlexW3162660398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.